Ovid Therapeutics Inc. (OVID) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
25/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinOVID / S&P 21.17% / 15.20% |
LoseOVID / S&P -76.20% / 15.00% |
LoseOVID / S&P OVID unavailable / 50.40% |
| 2026-Q12/3 |
WinOVID / S&P 36.20% / -4.33% |
WinOVID / S&P 1199.64% / 11.30% |
LoseOVID / S&P OVID unavailable / 27.70% |
| 2025-Q42/3 |
WinOVID / S&P 25.38% / 2.65% |
WinOVID / S&P 1181.27% / 9.00% |
LoseOVID / S&P OVID unavailable / 13.40% |
| 2025-Q32/3 |
WinOVID / S&P 293.94% / 8.12% |
WinOVID / S&P 945.89% / 4.61% |
LoseOVID / S&P OVID unavailable / 13.45% |
| 2025-Q21/3 |
LoseOVID / S&P 5.77% / 10.94% |
WinOVID / S&P 1070.95% / 4.83% |
LoseOVID / S&P OVID unavailable / 10.63% |
| 2025-Q11/3 |
LoseOVID / S&P -66.60% / -4.27% |
WinOVID / S&P 15.61% / 4.98% |
LoseOVID / S&P OVID unavailable / 10.57% |
| 2024-Q41/3 |
LoseOVID / S&P -20.85% / 2.41% |
WinOVID / S&P 44.39% / 5.25% |
LoseOVID / S&P OVID unavailable / 6.15% |
| 2024-Q32/3 |
WinOVID / S&P 53.45% / 5.89% |
WinOVID / S&P 113.31% / 5.89% |
LoseOVID / S&P -31.88% / 6.11% |
| 2024-Q21/3 |
LoseOVID / S&P -74.79% / 4.28% |
WinOVID / S&P 186.32% / 5.38% |
LoseOVID / S&P -38.57% / 5.12% |
| 2024-Q11/3 |
LoseOVID / S&P -5.28% / 10.56% |
WinOVID / S&P 284.17% / 5.71% |
LoseOVID / S&P 0.00% / 5.59% |
| 2023-Q40/3 |
LoseOVID / S&P -16.15% / 11.69% |
LoseOVID / S&P -73.91% / 6.81% |
LoseOVID / S&P -2.60% / 7.78% |
| 2023-Q31/3 |
WinOVID / S&P 17.07% / -3.27% |
LoseOVID / S&P -79.66% / 7.52% |
LoseOVID / S&P -30.30% / -5.03% |
| 2023-Q21/3 |
WinOVID / S&P 27.13% / 8.74% |
LoseOVID / S&P -86.27% / 9.50% |
LoseOVID / S&P -29.29% / -8.57% |
| 2023-Q11/3 |
WinOVID / S&P 38.71% / 7.50% |
LoseOVID / S&P -91.46% / 10.77% |
LoseOVID / S&P -27.72% / -15.69% |
| 2022-Q40/3 |
LoseOVID / S&P 1.09% / 7.56% |
LoseOVID / S&P -99.28% / 11.88% |
LoseOVID / S&P -144.00% / -17.99% |
| 2022-Q30/3 |
LoseOVID / S&P -14.42% / -4.88% |
LoseOVID / S&P -99.32% / 13.47% |
LoseOVID / S&P -155.62% / -1.41% |
| 2022-Q20/3 |
LoseOVID / S&P -31.53% / -16.10% |
LoseOVID / S&P -99.35% / 13.71% |
LoseOVID / S&P -159.28% / 11.04% |
| 2022-Q11/3 |
WinOVID / S&P -2.18% / -4.60% |
LoseOVID / S&P OVID unavailable / 15.97% |
LoseOVID / S&P -167.79% / 42.23% |
| 2021-Q40/3 |
LoseOVID / S&P -4.46% / 11.03% |
LoseOVID / S&P OVID unavailable / 15.00% |
LoseOVID / S&P -224.11% / 96.40% |
| 2021-Q30/3 |
LoseOVID / S&P -14.07% / 0.58% |
LoseOVID / S&P OVID unavailable / 10.77% |
LoseOVID / S&P OVID unavailable / 69.42% |
| 2021-Q20/3 |
LoseOVID / S&P -2.74% / 8.55% |
LoseOVID / S&P OVID unavailable / 6.58% |
LoseOVID / S&P OVID unavailable / 51.81% |
| 2021-Q11/3 |
WinOVID / S&P 74.03% / 6.17% |
LoseOVID / S&P OVID unavailable / -1.06% |
LoseOVID / S&P OVID unavailable / 7.39% |
| 2020-Q40/3 |
LoseOVID / S&P -59.76% / 12.15% |
LoseOVID / S&P OVID unavailable / -3.72% |
LoseOVID / S&P OVID unavailable / -33.42% |
| 2020-Q30/3 |
LoseOVID / S&P -22.12% / 8.93% |
LoseOVID / S&P OVID unavailable / -2.04% |
LoseOVID / S&P OVID unavailable / -27.10% |
| 2020-Q21/3 |
WinOVID / S&P 147.32% / 20.54% |
LoseOVID / S&P OVID unavailable / -0.46% |
LoseOVID / S&P OVID unavailable / -27.11% |
| 2020-Q10/3 |
LoseOVID / S&P -28.19% / -19.60% |
LoseOVID / S&P OVID unavailable / 3.47% |
LoseOVID / S&P OVID unavailable / -14.75% |
| 2019-Q41/3 |
WinOVID / S&P 28.09% / 9.07% |
LoseOVID / S&P OVID unavailable / 5.36% |
LoseOVID / S&P OVID unavailable / 2.99% |
| 2019-Q31/3 |
WinOVID / S&P 75.14% / 1.70% |
LoseOVID / S&P OVID unavailable / 5.02% |
LoseOVID / S&P OVID unavailable / 0.21% |
| 2019-Q21/3 |
WinOVID / S&P 4.52% / 4.30% |
LoseOVID / S&P OVID unavailable / 6.64% |
LoseOVID / S&P OVID unavailable / 8.65% |
| 2019-Q10/3 |
LoseOVID / S&P -26.86% / 13.65% |
LoseOVID / S&P OVID unavailable / 8.12% |
LoseOVID / S&P OVID unavailable / 14.29% |
| 2018-Q40/3 |
LoseOVID / S&P -57.32% / -13.52% |
LoseOVID / S&P OVID unavailable / 9.05% |
LoseOVID / S&P OVID unavailable / 18.23% |
| 2018-Q30/3 |
LoseOVID / S&P -27.31% / 7.71% |
LoseOVID / S&P OVID unavailable / 10.21% |
LoseOVID / S&P OVID unavailable / 19.06% |
| 2018-Q21/3 |
WinOVID / S&P 10.33% / 3.43% |
LoseOVID / S&P OVID unavailable / 9.03% |
LoseOVID / S&P OVID unavailable / 14.46% |
| 2018-Q10/3 |
LoseOVID / S&P -28.37% / -0.76% |
LoseOVID / S&P OVID unavailable / 7.68% |
LoseOVID / S&P OVID unavailable / 12.46% |
| 2017-Q41/3 |
WinOVID / S&P 15.17% / 6.64% |
LoseOVID / S&P OVID unavailable / 7.03% |
LoseOVID / S&P OVID unavailable / 13.82% |
| 2017-Q30/3 |
LoseOVID / S&P -18.30% / 4.48% |
LoseOVID / S&P OVID unavailable / 5.68% |
LoseOVID / S&P OVID unavailable / 17.57% |
| 2017-Q20/3 |
LoseOVID / S&P OVID unavailable / 3.09% |
LoseOVID / S&P OVID unavailable / 4.83% |
LoseOVID / S&P OVID unavailable / 17.74% |
| 2017-Q10/3 |
LoseOVID / S&P OVID unavailable / 6.07% |
LoseOVID / S&P OVID unavailable / 3.67% |
LoseOVID / S&P OVID unavailable / 13.32% |
| 2016-Q40/3 |
LoseOVID / S&P OVID unavailable / 3.82% |
LoseOVID / S&P OVID unavailable / 2.09% |
LoseOVID / S&P OVID unavailable / 7.05% |
| 2016-Q30/3 |
LoseOVID / S&P OVID unavailable / 3.85% |
LoseOVID / S&P OVID unavailable / 0.20% |
LoseOVID / S&P OVID unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | OVID total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 128.91% | 20.78% |
| Annualized return | 128.91% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | OVID total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -17.70% | 83.14% |
| Annualized return | -3.82% | 12.86% |
10Y · 2017-05-05 to 2026-08-27
| Metric | OVID total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -76.08% | 319.30% |
| Annualized return | -13.33% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |